Literature DB >> 9566395

Charcot-Marie-Tooth disease type 1A with 17p duplication in infancy and early childhood: a longitudinal clinical and electrophysiologic study.

A García1, O Combarros, J Calleja, J Berciano.   

Abstract

OBJECTIVE: We describe longitudinal clinical and electrophysiologic evaluation of Charcot-Marie-Tooth disease type 1A (CMT-1A) in infancy and early childhood.
BACKGROUND: The clinical picture and electrophysiologic evaluation of CMT-1A during the age of nerve conduction maturation have not been documented. DESIGN/
METHODS: Twenty at-risk children from six unrelated CMT-1A families were examined in the first 5 years of life. Initial ages were 1 month to 4 years (mean, 1.5 years) and final ages 4 to 19 years (mean, 9 years). All subjects had two or more motor and sensory conduction velocities (MCV and SCV), corrected distal motor latencies (DML), and F-waves.
RESULTS: Twelve children were affected. Initially, two of these (17%) had symptoms, whereas five (42%) were symptomatic at the end. Numbers of abnormal examinations at the beginning was six (50%) and at conclusion was 10 (83%). None of the patients were disabled. From 2 years of age, all affected children had abnormal MCV, SVC, F-waves, and DML. Prolonged DML was already present in the first months of life and preceded slowing of MCV in three cases.
CONCLUSION: The electrophysiologic studies were concordant with the presence or absence of the CMT-1A DNA duplication. In most CMT-1A patients, symptoms appear in early childhood, although the florid clinical picture does not occur until the second decade of life. Serial electrophysiologic studies can detect the CMT-1A gene carrier in infancy.

Entities:  

Mesh:

Year:  1998        PMID: 9566395     DOI: 10.1212/wnl.50.4.1061

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom.

Authors:  L Kalaydjieva; D Gresham; R Gooding; L Heather; F Baas; R de Jonge; K Blechschmidt; D Angelicheva; D Chandler; P Worsley; A Rosenthal; R H King; P K Thomas
Journal:  Am J Hum Genet       Date:  2000-05-30       Impact factor: 11.025

2.  NEFL E396K mutation is associated with a novel dominant intermediate Charcot-Marie-Tooth disease phenotype.

Authors:  José Berciano; Antonio García; Kristien Peeters; Elena Gallardo; Els De Vriendt; Ana L Pelayo-Negro; Jon Infante; Albena Jordanova
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

3.  Peripheral myelin protein 22 is in complex with alpha6beta4 integrin, and its absence alters the Schwann cell basal lamina.

Authors:  Stephanie A Amici; William A Dunn; Andrew J Murphy; Niels C Adams; Nicholas W Gale; David M Valenzuela; George D Yancopoulos; Lucia Notterpek
Journal:  J Neurosci       Date:  2006-01-25       Impact factor: 6.167

Review 4.  New insights into the pathophysiology of pes cavus in Charcot-Marie-Tooth disease type 1A duplication.

Authors:  José Berciano; Elena Gallardo; Antonio García; Ana L Pelayo-Negro; Jon Infante; Onofre Combarros
Journal:  J Neurol       Date:  2011-05-18       Impact factor: 4.849

5.  Clinical progression in Charcot-Marie-Tooth disease type 1A duplication: clinico-electrophysiological and MRI longitudinal study of a family.

Authors:  José Berciano; Elena Gallardo; Antonio García; César Ramón; Jon Infante; Onofre Combarros
Journal:  J Neurol       Date:  2010-05-05       Impact factor: 4.849

6.  Nerve conduction velocity in CMT1A: what else can we tell?

Authors:  F Manganelli; C Pisciotta; M M Reilly; S Tozza; A Schenone; G M Fabrizi; T Cavallaro; G Vita; L Padua; F Gemignani; M Laurà; R A C Hughes; A Solari; D Pareyson; L Santoro
Journal:  Eur J Neurol       Date:  2016-07-14       Impact factor: 6.089

7.  Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation.

Authors:  Elena Gallardo; Kristl G Claeys; Eva Nelis; Antonio García; Ana Canga; Onofre Combarros; Vincent Timmerman; Peter De Jonghe; José Berciano
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

8.  Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.

Authors:  Camiel Verhamme; Rob J de Haan; Marinus Vermeulen; Frank Baas; Marianne de Visser; Ivo N van Schaik
Journal:  BMC Med       Date:  2009-11-12       Impact factor: 8.775

9.  Remodeling of motor nerve terminals in demyelinating axons of periaxin-null mice.

Authors:  Felipe A Court; Peter J Brophy; Richard R Ribchester
Journal:  Glia       Date:  2008-03       Impact factor: 7.452

10.  Charcot–Marie–Tooth disease type 2J with MPZ Thr124Met mutation: clinico-electrophysiological and MRI study of a family.

Authors:  Elena Gallardo; Antonio García; César Ramón; Elías Maraví; Jon Infante; Itziar Gastón; Ángel Alonso; Onofre Combarros; Peter De Jonghe; José Berciano
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.